Assetmark Inc. Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Assetmark Inc. purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,214 shares of the biotechnology company’s stock, valued at approximately $331,000.

Other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after purchasing an additional 234,446 shares in the last quarter. Avoro Capital Advisors LLC increased its position in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the last quarter. Fred Alger Management LLC raised its stake in Ascendis Pharma A/S by 65.0% in the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares in the last quarter. Finally, Tri Locum Partners LP lifted its position in Ascendis Pharma A/S by 102.1% during the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after purchasing an additional 115,092 shares during the last quarter.

Ascendis Pharma A/S Stock Up 1.8 %

NASDAQ:ASND opened at $126.51 on Friday. The firm has a market capitalization of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66. The company has a fifty day moving average of $132.30 and a 200 day moving average of $132.66. Ascendis Pharma A/S has a 52 week low of $90.13 and a 52 week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -7.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday. Evercore ISI upped their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. The Goldman Sachs Group increased their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.